Expression of Shelterin Component POT1 Is Associated with Decreased Telomere Length and Immunity Condition in Humans with Severe Aplastic Anemia

Table 2

Clinical and demographic parameters of patients participating in the study.

Diagnosis	Number	Age (y)	Duration; (mo)	ANC; (/mm^3)	Hb; (g/dL)	Plts; (10^3/mm^3)	Ret%	Therapy
Untreated SAA	9	33 (5–69)	2 (1–4)	0.31±0.20	82.11±20.01	11.22±5.85	0.45±0.39	Not previously treated except for transfusions
Recovering SAA	18	20 (5–48)	24 (6–120)	3.33±1.22	118.94±16.78	89.35±43.08	1.14±0.27	Treated with combination indicated
Recovering group before combination treatment except transfusion	18	18 (4–47)	Unable to be determined for some patients	0.21±0.15	72.12±23.58	9.71±4.89	0.25±0.20	Not previously treated except for transfusions

Values are mean ± SEM. Age and duration values are mid (min, max). ANC: absolute neutrophil count; Hb: hemoglobin; Plt: platelet; Ret: reticulocyte.